Differential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington’s disease

Frontiers in Systems Neuroscience

Volumn 8, Issue OCT, 2014, Pages

  Deng, Yun Ping ^a   Wong, Ting ^a   Wan, Jim Y ^a   Reiner, Anton ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Corticostriatal; Huntington s disease; Pathology; Premanifest; Thalamostriatal

Indexed keywords

DOPAMINE 1 RECEPTOR; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR GLUTAMATE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORTICAL THICKNESS (BRAIN); CORTICOSTRIATAL TERMINAL; DENDRITE; ELECTRON MICROSCOPY; HUNTINGTON CHOREA; HYPOKINESIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE INJURY; NONHUMAN; NONPARAMETRIC TEST; OPEN FIELD TEST; PHENOTYPE; THALAMOSTRIATAL TERMINAL;

EID: 84908001567     PISSN: 16625137     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnsys.2014.00198     Document Type: Article

References (147)

1. Aggerman, K., and Ernfors, P. (2003). Differential influence of BDNF and NT3 on the expression of calcium binding proteins and neuropeptide Y in vivo. Neuroreport 14, 2183-2187. doi: 10.1097/00001756-200312020-00010
2. Albin, R. L., Qin, Y., Young, A. B., Penney, J. B., and Chesselet, M. F. (1991). Preproenkephalin messenger RNA-containing neurons in striatum of patients with symptomatic and presymptomatic Huntington's disease: an in situ hybridization study. Ann. Neurol. 30, 542-549. doi: 10.1002/ana.410300406
3. Albin, R. L., Young, A. B., and Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375. doi: 10.1016/0166-2236(89)90074-X
4. Alcantara, S., Frisen, J., del Rio, J. A., Soriano, E., Barbacid, M., and Silos-Santiago, I. (1997). TrkB signaling is required for postnatal survival of CNS neurons and protects hippocampal and motor neurons from axotomy-induced cell death. J. Neurosci. 17, 3623-3633.
5. André, V. M., Cepeda, C., Fisher, Y. E., Huynh, M., Bardakjian, N., Singh, S., et al. (2011a). Differential electrophysiological changes in striatal output neurons in Huntington's disease. J. Neurosci. 31, 1170-1182. doi: 10.1523/JNEUROSCI.3539-10.2011
6. André, V. M., Fisher, Y. E., and Levine, M. S. (2011b). Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease. Front. Syst. Neurosci. 5:46. doi: 10.3389/fnsys.2011.00046
7. Augood, S. J., Faull, R. L., and Emson, P. C. (1997). Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 42, 215-221. doi: 10.1002/ana.410420213
8. Aylward, E. H., Nopoulos, P. C., Ross, C. A., Langbehn, D. R., Pierson, R. K., Mills, J. A., et al. (2011). Longitudinal change in regional brain volumes in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry 82, 405-410. doi: 10.1136/jnnp.2010.208264
9. Bacci, J. J., Kachidian, P., Kerkerian-Le Goff, L., and Salin, P. (2004). Intralaminar thalamic nuclei lesions: widespread impact on dopamine denervation-mediated cellular defects in the rat basal ganglia. J. Neuropathol. Exp. Neurol. 63, 20-31.
10. Bacci, J. J., Kerkerian-Le Goff, L., and Salin, P. (2002). Effects of intralaminar thalamic nuclei lesion on glutamic acid decarboxylase (GAD65 and GAD67) and cytochrome oxidase subunit I mRNA expression in the basal ganglia of the rat. Eur. J. Neurosci. 15, 1918-1928. doi: 10.1046/j.1460-9568.2002.02039.x
11. Baquet, Z. C., Gorski, J. A., and Jones, K. R. (2004). Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 24, 4250-4258. doi: 10.1523/JNEUROSCI.3920-03.2004
12. Baydyuk, M., Russell, T., Liao, G. Y., Zang, K., An, J. J., Reichardt, L. F., et al. (2011). TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons. Proc. Natl. Acad. Sci. U.S.A. 108, 1669-1674. doi: 10.1073/pnas.1004744108
13. Bechtel, N., Scahill, R. I., Rosas, H. D., Acharya, T., van den Bogaard, S. J., Jauffret, C., et al. (2010). Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 75, 2150-2160. doi: 10.1212/WNL.0b013e3182020123
14. Benn, C. L., Slow, E. J., Farrell, L. A., Graham, R., Deng, Y., Hayden, M. R., et al. (2007). Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience 147, 354-372. doi: 10.1016/j.neuroscience.2007.03.010
15. Berendse, H. W., and Groenewegen, H. J. (1990). Organization of the thalamostriatal projections in the rat, with special emphasis on the ventral striatum. J. Comp. Neurol. 299, 187-228. doi: 10.1002/cne.902990206
16. Biglan, K. M., Ross, C. A., Langbehn, D. R., Aylward, E. H., Stout, J. C., Queller, S., et al. (2009). Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov. Disord. 24, 1763-1772. doi: 10.1002/mds.22601
17. Blekher, T. M., Yee, R. D., Kirkwood, S. C., Hake, A. M., Stout, J. C., Weaver, M. R., et al. (2004). Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. Vis. Res. 44, 2729-2736. doi: 10.1016/j.visres.2004.06.006
18. Canals, J. M., Pineda, J. R., Torres-Peraza, J. F., Bosch, M., Martin-Ibanez, R., Muñoz, M. T., et al. (2004). Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24, 7727-7739. doi: 10.1523/JNEUROSCI.1197-04.2004
19. Cattaneo, E., Rigamonti, D., Goffredo, D., Zuccato, C., Squitieri, F., and Sipione, S. (2001). Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 24, 182-188. doi: 10.1016/S0166-2236(00)01721-5
20. Cattaneo, E., Zuccato, C., and Tartari, M. (2005). Normal Huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919-930. doi: 10.1038/nrn1806
21. Cepeda, C., André, V. M., Yamazaki, I., Wu, N., Kleiman-Weiner, M., and Levine, M. S. (2008). Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons.Eur. J. Neurosci. 27, 671-682. doi: 10.1111/j.1460-9568.2008.06038.x
22. Cepeda, C., Hurst, R. S., Calvert, C. R., Hernández-Echeagaray, E., Nguyen, O. K., Jocoy, E., et al. (2003). Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 23, 961-969.
23. Ciarmiello, A., Cannella, M., Lastoria, S., Simonelli, M., Frati, L., Rubinsztein, D. C., et al. (2006). Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 47, 215-222.
24. Crittenden, J. R., and Graybiel, A. M. (2011). Basal ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front Neuroanat. 5:59. doi: 10.3389/fnana.2011.00059
25. Cummings, D. M., Cepeda, C., and Levine, M. S. (2010). Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro 2, e00036. doi: 10.1042/AN20100007
26. Day, M., Wang, Z., Ding, J., An, X., Ingham, C. A., Shering, A. F., et al. (2006). Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 9, 251-259. doi: 10.1038/nn1632
27. de Boo, G. M., Tibben, A., Lanser, J. B., Jennekens-Schinkel, A., Hermans, J., Maat-Kievit, A., et al. (1997). Early cognitive and motor symptoms in identified carriers of the gene for Huntington disease. Arch. Neurol. 54, 1353-1357. doi: 10.1001/archneur.1997.00550230030012
28. Delval, A., Bleuse, S., Simonin, C., Delliaux, M., Rolland, B., Destee, A., et al. (2011). Are gait initiation parameters early markers of Huntington's disease in pre-manifest mutation carriers? Gait Posture 34, 202-207. doi: 10.1016/j.gaitpost.2011.04.011
29. Deng, Y. P., Albin, R. L., Penney, J. B., Young, A. B., Anderson, K. D., and Reiner, A. (2004). Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J. Chem. Neuroanat. 27, 143-164. doi: 10.1016/j.jchemneu.2004.02.005
30. Deng, Y. P., Wong, T., Bricker-Anthony, C., Deng, B., and Reiner, A. (2012). Patterns of loss of corticostriatal and thalamostriatal terminals from direct and indirect pathway projection neurons and cholinergic interneurons in Q140 Huntington's disease knock-in mice. Soc. Neurosci. Abstr. (Accession No. 154.26/G40).
31. Deng, Y. P., Wong, T., Bricker-Anthony, C., Deng, B., and Reiner, A. (2013). Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice. Neurobiol. Dis. 60, 89-107. doi: 10.1016/j.nbd.2013.08.009
32. Desban, M., Kemel, M. L., Glowinski, J., and Gauchy, C. (1993). Spatial organization of patch and matrix compartments in the rat striatum. Neuroscience 57, 661-667. doi: 10.1016/0306-4522(93)90013-6
33. Ding, J. B., Oh, W. J., Sabatini, B. L., and Gu, C. (2011). Semaphorin 3E-Plexin-D1 signaling controls pathway-specific synapse formation in the striatum. Nat. Neurosci. 15, 215-223. doi: 10.1038/nn.3003
34. DiProspero, N. A., Chen, E. Y., Charles, V., Plomann, M., Kordower, J. H., and Tagle, D. A. (2004). Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol. 33, 517-533. doi: 10.1007/s11068-004-0514-8
35. Doig, N. M., Moss, J., and Bolam, J. P. (2010). Cortical and thalamic innervation of direct and indirect pathway medium-sized spiny neurons in mouse striatum. J. Neurosci. 30, 14610-14618. doi: 10.1523/JNEUROSCI.1623-10.2010
36. Douaud, G., Gaura, V., Ribeiro, M. J., Lethimonnier, F., Maroy, R., Verny, C., et al. (2006). Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study.Neuroimage 32, 1562-1575. doi: 10.1016/j.neuroimage.2006.05.057
37. Doyle, J. P., Dougherty, J. D., Heiman, M., Schmidt, E. F., Stevens, T. R., Ma, G., et al. (2008). Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell 135, 749-762. doi: 10.1016/j.cell.2008.10.029
38. Drai, D., Benjamini, Y., and Golani, I. (2000). Statistical discrimination of natural modes of motion in rat exploratory behavior. J. Neurosci. Methods 96, 119-131. doi: 10.1016/S0165-0270(99)00194-6
39. Drai, D., and Golani, I. (2001). SEE: a tool for the visualization and analysis of rodent exploratory behavior.Neurosci. Biobehav. Rev. 25, 409-426. doi: 10.1016/S0149-7634(01)00022-7
40. Dumas, E. M., van den Bogaard, S. J., Ruber, M. E., Reilman, R. R., Stout, J. C., Craufurd, D., et al. (2012). Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Hum. Brain Mapp. 33, 203-212. doi: 10.1002/hbm.21205
41. Estrada-Sanchez, A., and Rebec, V. G. (2013). Role of cerebral cortex in the neuropathology of Huntington's disease. Front. Neural Circuits 7:19. doi: 10.3389/fncir.2013.00019.
42. Feigin, A., Tang, C., Ma, Y., Mattis, P., Zgaljardic, D., Guttman, M., et al. (2007). Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 130, 2858-2867. doi: 10.1093/brain/awm217
43. Ferrante, R. J., Kowall, N. W., Beal, M. F., Martin, J. B., Bird, E. D., Richardson, E. P., et al. (1987). Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 46, 12-27. doi: 10.1097/00005072-198701000-00002
44. Freeman, W., and Morton, A. J. (2004). Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation. Brain Res. Bull. 63, 45-55. doi: 10.1016/j.brainresbull.2003.12.004
45. Fremeau, R. T., Troyer, M. D., Pahner, I., Nygaard, G. O., Tran, C. H., Reiner, R. J., et al. (2001). The expression of vesicular glutamate transporters defines two classes of excitatory synapse. Neuron 31, 247-260. doi: 10.1016/S0896-6273(01)00344-0
46. Gauthier, L. R., Charrin, B. C., Borrell-Pages, M., Dompierre, J. P., Rangone, H., Cordelières, F. P., et al. (2004). Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127-138. doi: 10.1016/j.cell.2004.06.018
47. Gerfen, C. R. (1992). The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia.Annu. Rev. Neurosci. 15, 285-320. doi: 10.1146/annurev.ne.15.030192.001441
48. Gharami, K., Xie, Y., An, J. J., Tonegawa, S., and Xu, B. (2008). Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem. 105, 369-379. doi: 10.1111/j.1471-4159.2007.05137.x
49. Giorgi, S., Rimoldi, M., and Consolo, S. (2001). Parafascicular thalamic nucleus deafferentation reduces c-fos expression induced by dopamine D-1 receptor stimulation in rat striatum. Neuroscience 103, 653-661. doi: 10.1016/S0306-4522(01)00002-1
50. Giralt, A., Carretón, O., Lao-Peregrin, C., Martín, E. D., and Alberch, J. (2011). Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. Mol. Neurodegener. 6, 71-86. doi: 10.1186/1750-1326-6-71
51. Glass, M., Dragunow, M., and Faull, R. L. M. (2000). The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAa receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505-519. doi: 10.1016/S0306-4522(00)00008-7
52. Gorski, J. A., Zeiler, S. R., Tamowski, S., and Jones, K. R. (2003). Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. J. Neurosci. 23, 6856-6865.
53. Grafton, S. T., Mazziotta, J. C., Pahl, J. J., St. George-Hyslop, P., Haines, J. L., Gusella, J., et al. (1992). Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch. Neurol. 49, 1161-1167. doi: 10.1001/archneur.1992.00530350075022
54. Graham, R. K., Pouladi, M. A., Joshi, P., Lu, G., Deng, Y., Wu, N. P., et al. (2009). Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J. Neurosci. 29, 2193-2204. doi: 10.1523/JNEUROSCI.5473-08.2009
55. Grosse, G., Djalali, S., Deng, D. R., Holtje, M., Hinz, B., Schwartzkopff, K., et al. (2005). Area-specific effects of brain-derived neurotrophic factor (BDNF) genetic ablation on various neuronal subtypes of the mouse brain. Dev. Brain Res. 156, 111 -126. doi: 10.1016/j.devbrainres.2004.12.012
56. Hansson, O., Guatteo, E., Mercuri, N. B., Bernardi, G., Li, X. J., Castilho, R. F., et al. (2001). Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur. J. Neurosci. 14, 1492-1504. doi: 10.1046/j.0953-816x.2001.01767.x
57. Hansson, O., Petersén, A., Leist, M., Nicotera, P., Castilho, R. F., and Brundin, P. (1999). Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. U.S.A. 96, 8727-8732. doi: 10.1073/pnas.96.15.8727
58. Hedreen, J. C., and Folstein, S. E. (1995). Early loss of neostriatal striosome neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 54, 105-120. doi: 10.1097/00005072-199501000-00013
59. Heinsen, H., Rüb, U., Bauer, M., Ulmar, G., Bethke, B., Schüler, M., et al. (1999). Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol. 97, 613-622. doi: 10.1007/s004010051037
60. Hersch, S. M., Ciliax, B. J., Gutekunst, C. A., Rees, H. D., Heilman, C. J., Yung, K. K., et al. (1995). Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci. 15, 5222-5237.
61. Hickey, M. A., Kosmalska, A., Enayati, J., Cohen, R., Zeitlin, S., Levine, M. S., et al. (2008). Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.Neuroscience 157, 280-295. doi: 10.1016/j.neuroscience.2008.08.041
62. Hickey, M. A., Zhu, C., Medvedeva, V., Lerner, R. P., Patassini, S., Franich, N. R., et al. (2012). Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Mol. Neurodegener. 7, 12. doi: 10.1186/1750-1326-7-12
63. Hobbs, N. Z., Barnes, J., Frost, C., Henley, S. M., Wild, E. J., Macdonald, K., et al. (2010a). Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am. J. Neuroradiol. 31, 1036-1041. doi: 10.3174/ajnr.A2018
64. Huerta-Ocampo, I., Mena-Segovia, J., and Bolam, J. P. (2014). Convergence of cortical and thalamic input to direct and indirect pathway medium spiny neurons in the striatum. Brain Struct. Funct. 219, 1787-1800. doi: 10.1007/s00429-013-0601-z
65. Ivkovic, S., and Ehrlich, M. E. (1999). Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J. Neurosci. 19, 5409-5419.
66. Joshi, P. R., Wu, N. P., André, V. M., Cummings, D. M., Cepeda, C., Joyce, J. A., et al. (2009). Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 29, 2414-2427. doi: 10.1523/JNEUROSCI.5687-08.2009
67. Kafkafi, N., Lipkind, D., Benjamini, Y., Mayo, C. L., Elmer, G. I., and Golani, I. (2003). SEE locomotor behavior test discriminates C57BL/6J and DBA/2J mouse inbred strains across laboratories and protocol conditions. Behav. Neurosci. 117, 464-477. doi: 10.1037/0735-7044.117.3.464
68. Kafkafi, N., Mayo, C., Drai, D., Golani, I., and Elmer, G. (2001). Natural segmentation of the locomotor behavior of drug-induced rats in a photobeam cage. J. Neurosci. Methods 109, 111-121. doi: 10.1016/S0165-0270(01)00392-2
69. Kassubek, J., Juengling, F. D., Kioschies, T., Henkel, K., Karitzky, J., Kramer, B., et al. (2004b). Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J. Neurol. Neurosurg. Psychiatry 75, 213-220.
70. Kipps, C. M., Duggins, A. J., Mahant, N., Gomes, L., Ashburner, J., and McCusker, E. A. (2005). Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J. Neurol. Neurosurg. Psychiatry 76, 650-655. doi: 10.1136/jnnp.2004.047993
71. Kirkwood, S. C., Siemers, E., Bond, C., Conneally, P. M., Christian, J. C., and Foroud, T. (2000). Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch. Neurol. 57, 1040-1044. doi: 10.1001/archneur.57.7.1040
72. Kirkwood, S. C., Siemers, E., Stout, J. C., Hodes, M. E., Conneally, P. M., Christian, J. C., et al. (1999). Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch. Neurol. 56, 563-568. doi: 10.1001/archneur.56.5.563
73. Klapstein, G. J., Fisher, R. S., Zanjani, H., Cepeda, C., Jokel, E. S., Chesselet, M. F., et al. (2001). Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 86, 2667-2677.
74. Kravitz, A. V., Freeze, B. S., Parker, P. R., Kay, K., Thwin, M. T., Deisseroth, K., et al. (2010). Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466, 622-626. doi: 10.1038/nature09159
75. Kuhn, A., Goldstein, D. R., Hodges, A., Strand, A. D., Sengstag, T., Kooperberg, C., et al. (2007). Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Gen. 16, 1845-1861. doi: 10.1093/hmg/ddm133
76. Kusakabe, M., Mangiarini, L., Laywell, E. D., Bates, G. P., Yoshiki, A., Hiraiwa, N., et al. (2001). Loss of cortical and thalamic neuronal tenascin-C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene. J. Comp. Neurol. 430, 485-500. doi: 10.1002/1096-9861(20010219)430:4<485::AID-CNE1045>3.0.CO;2-6
77. Lapper, S. R., and Bolam, J. P. (1992). Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience 51, 533-545. doi: 10.1016/0306-4522(92)90293-B
78. Lei, W., Deng, Y. P., Liu, B. B., Mu, S. H., Guley, N. M., Wong, T., et al. (2013). A confocal laser scanning microscopy and ultrastructural study of VGLUT2 thalamic input to striatal projection neurons in rats. J. Comp. Neurol. 521, 1354-1377. doi: 10.1002/cne.23235
79. Lei, W., Jiao, Y., Del Mar, N., and Reiner, A. (2004). Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J. Neurosci. 24, 8289-8299. doi: 10.1523/JNEUROSCI.1990-04.2004
80. Lerner, R. P., Trejo Martinez Ldel, C., Zhu, C., Chesselet, M. F., and Hickey, M. A. (2012). Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease. Brain Res. Bull. 87, 571-578. doi: 10.1016/j.brainresbull.2012.01.012
81. Levey, A. I., Hersch, S. M., Rye, D. B., Sunahara, R. K., Niznik, H. B., Kitt, C. A., et al. (1993). Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc. Natl. Acad. Sci. U.S.A. 90, 8861-8865. doi: 10.1073/pnas.90.19.8861
82. Lipkind, D., Sakov, A., Kafkafi, N., Elmer, G. I., Benjamini, Y., and Golani, I. (2004). New replicable anxiety-related measures of wall vs center behavior of mice in the open field. J. Appl. Physiol. 97, 347-359. doi: 10.1152/japplphysiol.00148.2004
83. Martınez-Serrano, A., and Bjorklund, A. (1996). Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J. Neurosci. 16, 4604-4616.
84. Melone, M., Burette, A., and Weinberg, R. J. (2005). Light microscopic identification and immunocytochemical characterization of glutamatergic synapses in brain sections. J. Comp. Neurol. 492, 495-509. doi: 10.1002/cne.20743
85. Menalled, L. B., Sison, J. D., Dragatsis, I., Zeitlin, S., and Chesselet, M. F. (2003). Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 465, 11-26. doi: 10.1002/cne.10776
86. Menalled, L. B., Sison, J. D., Wu, Y., Olivieri, M., Li, X. J., Li, H., et al. (2002). Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 22, 8266-8276.
87. Menalled, L., Zanjani, H., MacKenzie, L., Koppel, A., Carpenter, E., Zeitlin, S., et al. (2000). Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp. Neurol. 162, 328-342. doi: 10.1006/exnr.1999.7327
88. Mizuno, K., Carnahan, J., and Nawa, H. (1994). Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev. Biol. 165, 243-256. doi: 10.1006/dbio.1994.1250
89. Montana, N., Ni, Y., Sunjara, V., Hua, X., and Parpura, V. (2004). Vesicular glutamate transporter-dependent glutamate release from astrocytes. J. Neurosci. 24, 2633-2642. doi: 10.1523/JNEUROSCI.3770-03.2004
90. Mühlau, M., Weindl, A., Wohlschläger, A. M., Gaser, C., Städtler, M., Valet, M., et al. (2007). Voxel-based morphometry indicates relative preservation of the limbic prefrontal cortex in early Huntington disease. J. Neural. Transm. 114, 367-372. doi: 10.1007/s00702-006-0571-x
91. Nakao, N., Brundin, P., Funa, K., Lindvall, O., and Odin, P. (1995). Trophic and protective actions of brain-derived neurotrophic factor on striatal DARPP-32-containing neurons in vitro. Dev. Brain Res. 90, 92-101. doi: 10.1016/0165-3806(96)83489-4
92. Nopoulos, P. C., Aylward, E. H., Ross, C. A., Johnson, H. J., Magnotta, V. A., Juhl, A. R., et al. (2010). Cerebral cortex structure in prodromal Huntington disease. Neurobiol. Dis. 40, 544-554. doi: 10.1016/j.nbd.2010.07.014
93. Paulsen, J. S., Magnotta, V. A., Mikos, A. E., Paulson, H. L., Penziner, E., Andreasen, N. C., et al. (2006). Brain structure in preclinical Huntington's disease. Biol. Psychiatry 59, 57-63. doi: 10.1016/j.biopsych.2005.06.003
94. Paulsen, J. S., Zimbelman, J. L., Hinton, S. C., Langbehn, D. R., Leveroni, C. L., Benjamin, M. L., et al. (2004). fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. AJNR Am. J. Neuroradiol. 25, 1715-1721.
95. Rao, A. K., Gordon, A. M., and Marder, K. S. (2011). Coordination of fingertip forces during precision grip in premanifest Huntington's disease. Mov. Disord. 26, 862-869. doi: 10.1002/mds.23606
96. Rao, A. K., Muratori, L., Louis, E. D., Moskowitz, C. B., and Marder, K. S. (2008). Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov. Disord. 23, 1100-1107. doi: 10.1002/mds.21987
97. Reading, S. A., Yassa, M. A., Bakker, A., Dziorny, A. C., Gourley, L. M., Yallapragada, V., et al. (2005). Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res. 140, 55-62. doi: 10.1016/j.pscychresns.2005.05.011
98. Rebec, G. V., Conroy, S. K., and Barton, S. J. (2006). Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 137, 327-336. doi: 10.1016/j.neuroscience.2005.08.062
99. Reiner, A., Albin, R. L., Anderson, K. D., D'Amato, C. J., Penney, J. B., and Young, A. B. (1988). Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 85, 5733-5737. doi: 10.1073/pnas.85.15.5733
100. Reiner, A., Hart, N. M., Lei, W., and Deng, Y. (2010). Corticostriatal projection neurons - dichotomous types and dichotomous functions. Front. Neuroanat. 4:142. doi: 10.3389/fnana.2010.00142
101. Reiner, A., Jiao, Y., Del Mar, N., Laverghetta, A. V., and Lei, W. L. (2003). Differential morphology of pyramidal tract-type and intratelencephalically projecting-type corticostriatal neurons and their intrastriatal terminals in rats. J. Comp. Neurol. 457, 420-440. doi: 10.1002/cne.10541
102. Reiner, A., Lafferty, D. C., Wang, H. B., Del Mar, N., and Deng, Y. P. (2012a). The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice. Neurobiol. Dis. 47, 75-91. doi: 10.1016/j.nbd.2012.03.025
103. Reiner, A., Wang, H. B., Del Mar, N., Sakata, K., Yoo, W., and Deng, Y. P. (2012b). BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice. Brain Res. 1473, 161-172. doi: 10.1016/j.brainres.2012.07.026
104. Richfield, E. K., Maguire-Zeiss, K. A., Vonkeman, H. E., and Voorn, P. (1995). Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann. Neurol. 38, 852-861. doi: 10.1002/ana.410380605
105. Rising, A. C., Xu, J., Carlson, A., Napoli, V. V., Denovan-Wright, E. M., and Mandel, R. J. (2011). Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats. Exp. Neurol. 228, 173-182. doi: 10.1016/j.expneurol.2010.12.017
106. Rosas, H. D., Hevelone, N. D., Zaleta, A. K., Greve, D. N., Salat, D. H., and Fischl, B. (2005). Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65, 745-747. doi: 10.1212/01.wnl.0000174432.87383.87
107. Rosas, H. D., Koroshetz, W. J., Chen, Y. I., Skeuse, C., Vangel, M., Cudkowicz, M. E., et al. (2003). Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60, 1615-1620. doi: 10.1212/01.WNL.0000065888.88988.6E
108. Rosas, H. D., Tuch, D. S., Hevelone, N. D., Zaleta, A. K., Vangel, M., Hersch, S. M., et al. (2006). Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov. Disord. 21, 1317-1325. doi: 10.1002/mds.20979
109. Rupp, J., Blekher, T., Jackson, J., Beristain, X., Marshall, J., Hui, S., et al. (2010). Progression in prediagnostic Huntington disease. J. Neurol. Neurosurg. Psychiatry 81, 379-384. doi: 10.1136/jnnp.2009.176982
110. Salin, P., and Kachidian, P. (1998). Thalamo-striatal deafferentation affects preproenkephalin but not preprotachykinin gene expression in the rat striatum. Brain Res. Mol. Brain Res. 57, 257-265. doi: 10.1016/S0169-328X(98)00098-9
111. Saylor, A. J., Meredith, G. E., Vercillo, M. S., Zahm, D. S., and McGinty, J. F. (2006). BDNF heterozygous mice demonstrate age-related changes in striatal and nigral gene expression. Exp. Neurol. 199, 362-372. doi: 10.1016/j.expneurol.2006.01.004
112. Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., et al. (2012). Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691-705. doi: 10.1016/j.neuron.2012.03.026
113. Seto-Ohshima, A., Emson, P. C., Lawson, E., Mountjoy, C. Q., and Carrasco, L. H. (1988). Loss of matrix calcium-binding protein-containing neurons in Huntington's disease. Lancet 331, 1252-1255. doi: 10.1016/S0140-6736(88)92073-9
114. Sidibé, M., and Smith, Y. (1996). Differential synaptic innervation of striatofugal neurones projecting to the internal or external segments of the globus pallidus by thalamic afferents in the squirrel monkey. J. Comp. Neurol. 365, 445-465.
115. Sidibé, M., and Smith, Y. (1999). Thalamic inputs to striatal interneurons in monkeys: synaptic organization and co-localization of calcium binding proteins. Neuroscience 89, 1189-1208. doi: 10.1016/S0306-4522(98)00367-4
116. Siemers, E., Foroud, T., Bill, D. J., Sorbel, J., Norton, J. A. Jr., Hodes, M. E., et al. (1996). Motor changes in presymptomatic Huntington disease gene carriers. Arch. Neurol. 53, 487-492. doi: 10.1001/archneur.1996.00550060029011
117. Singaraja, R. R., Huang, K., Sanders, S. S., Milnerwood, A. J., Hines, R., Lerch, J. P., et al. (2011). Altered palmitoylation and neuropathological deficits in mice lacking HIP14. Hum. Mol. Genet. 20, 3899-3909. doi: 10.1093/hmg/ddr308
118. Slow, E. J., van Raamsdonk, J., Rogers, D., Coleman, S. H., Graham, R. K., Deng, Y., et al. (2003). Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12, 1555-1567. doi: 10.1093/hmg/ddg169
119. Smith, Y., Raju, D. V., Pare, J. P., and Sidibe, M. (2004). The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 27, 520-527. doi: 10.1016/j.tins.2004.07.004
120. Smith, Y., Surmeier, D. J., Redgrave, P., and Kimura, M. (2011). Thalamic contributions to basal ganglia-related behavioral switching and reinforcement. J. Neurosci. 31, 16102-16106. doi: 10.1523/JNEUROSCI.4634-11.2011
121. Spigolon, G., Furth, D., Bonito-Oliva, A., Xuan, Y., Pollak Dorocic, I., Yoo, E., et al. (2013). Anatomical and Functional Characterization of the Cortical Input to D1 or D2 Receptor-Expressing Striatal Neurons. Alghero: Dopamine 2013.
122. Strand, A. D., Baquet, Z. C., Aragaki, A. K., Holmans, P., Yang, L., Cleren, C., et al. (2007). Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J. Neurosci. 27, 11758-11768. doi: 10.1523/JNEUROSCI.2461-07.2007
123. Sun, Z., Del Mar, N., Meade, C., Goldowitz, D., and Reiner, A. (2002). Differential changes in striatal projection neurons in R6/2 mice transgenic for Huntington's disease. Neurobiol. Dis. 11, 369-385. doi: 10.1006/nbdi.2002.0554
124. Tabrizi, S. J., Scahill, R. I., Durr, A., Roos, R. A., Leavitt, B. R., Jones, R., et al. (2011). Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 10, 31-42. doi: 10.1016/S1474-4422(10)70276-3
125. Tian, X., Kai, L., Hockberger, P. E., Wokosin, D. L., and Surmeier, D. J. (2010). MEF-2 regulates activity-dependent spine loss in striatopallidal medium spiny neurons. Mol. Cell. Neurosci. 44, 94-108. doi: 10.1016/j.mcn.2010.01.012
126. Tong, X., Ao, Y., Faas, G. C., Nwaobi, S. E., Xu, J., Haustein, M. D., et al. (2014). Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat. Neurosci. 17, 694-703. doi: 10.1038/nn.3691
127. Turner, T. H., Goldstein, J., Hamilton, J. M., Jacobson, M., Pirogovsky, E., Peavy, G., et al. (2011). Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. J. Mot. Behav. 43, 295-302. doi: 10.1080/00222895.2011.580390
128. Ventimiglia, R., Mather, P. E., Jones, B. E., and Lindsay, R. M. (1995). The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur. J. Neurosci. 7, 213-222. doi: 10.1111/j.1460-9568.1995.tb01057.x
129. Vonsattel, J. P., and DiFiglia, M. (1998). Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 57, 369-384. doi: 10.1097/00005072-199805000-00001
130. Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D., Richardson, E. P., et al. (1985). Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577. doi: 10.1097/00005072-198511000-00003
131. Waldvogel, H. J., Thu, D., Hogg, V., Tippett, L., and Faull, R. L. (2012). Selective neurodegeneration, neuropathology and symptom profiles in Huntington's disease. Adv. Exp. Med. Biol. 769, 141-152. doi: 10.1007/978-1-4614-5434-2_9
132. Wall, N. R., De La Parra, M., Callaway, E. M., and Kreitzer, A. C. (2013). Differential innervation of direct- and indirect-pathway striatal projection neurons. Neuron 79, 347-360. doi: 10.1016/j.neuron.2013.05.014
133. Wang, H. B., Deng, Y. P., and Reiner, A. (2007). In situ hybridization histochemical and immunohistochemical evidence that striatal projection neurons co-containing substance P and enkephalin are overrepresented in the striosomal compartment of striatum in rats. Neurosci. Lett. 425, 195-199. doi: 10.1016/j.neulet.2007.08.033
134. Wang, H., and Pickel, V. M. (2002). Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudate-putamen nucleus. J. Comp. Neurol. 442, 392-404. doi: 10.1002/cne.10086
135. Wässle, H., Regus-Leidig, H., and Haverkamp, S. (2006). Expression of the vesicular glutamate transporter vGluT2 in a subset of cones of the mouse retina. J. Comp. Neurol. 496, 544-555. doi: 10.1002/cne.20942
136. Widmer, H. R., and Hefti, F. (1994). Neurotrophin-4/5 promotes survival and differentiation of rat striatal neurons developing in culture. Eur. J. Neurosci. 6, 1669-1679. doi: 10.1111/j.1460-9568.1994.tb00559.x
137. Wilson, C. J. (1987). Morphology and synaptic connections of crossed corticostriatal neurons in the rat. J. Comp. Neurol. 263, 567-580. doi: 10.1002/cne.902630408
138. Wilson, C. J., Groves, P. M., Kitai, S. T., and Linder, J. C. (1983). Three-dimensional structure of dendritic spines in the rat neostriatum. J. Neurosci. 3, 383-388.
139. Wolf, R. C., Grön, G., Sambataro, F., Vasic, N., Wolf, N. D., Thomann, P. A., et al. (2012). Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness. Hum. Brain Mapp. 33, 2161-2173. doi: 10.1002/hbm.21348
140. Wright, A. K., Norrie, L., Ingham, C. A., Hutton, E. A., and Arbuthnott, G. W. (1999). Double anterograde tracing of outputs from adjacent "barrel columns" of rat somatosensory cortex. Neostriatal projection patterns and terminal ultrastructure. Neuroscience 88, 119-133. doi: 10.1016/S0306-4522(98)00186-9
141. Wright, A. K., Ramanathan, S., and Arbuthnott, G. W. (2001). Identification of the source of the bilateral projection system from cortex to somatosensory neostriatum and an exploration of its physiological actions. Neuroscience103, 87-96. doi: 10.1016/S0306-4522(00)00564-9
142. Xie, Y., Hayden, M. R., and Xu, B. (2010). BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J. Neurosci. 30, 14708-14718. doi: 10.1523/JNEUROSCI.1637-10.2010
143. Zuccato, C., and Cattaneo, E. (2007). Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 81, 294-330. doi: 10.1016/j.pneurobio.2007.01.003
144. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., et al. (2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498. doi: 10.1126/science.1059581
145. Zuccato, C., Liber, D., Ramos, C., Tarditi, A., Rigamonti, D., Tartari, M., et al. (2005). Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 52, 133-139. doi: 10.1016/j.phrs.2005.01.001
146. Zuccato, C., Marullo, M., Conforti, P., McDonald, M. E., Tartari, M., and Cattaneo, E. (2008). Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 18, 225-238. doi: 10.1111/j.1750-3639.2007.00111.x
147. Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., et al. (2003). Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Gen. 35, 76-83. doi: 10.1038/ng1219